Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about cross-border ordering, and it is deliberately narrow — everything I am not confident about is marked as such.
The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines, and whether the shipment looks commercial. Personal-import allowances exist in some jurisdictions and not in others, and where they exist they are usually conditional on a prescription and a quantity limit. The failure mode is normally a seizure notice rather than anything worse, and a reshipment policy is the thing worth confirming before ordering rather than after.
Cold chain is the underrated risk on long routes. A shipment held at a border for a week has had a temperature excursion whether or not it arrives.
So the question, as narrowly as I can put it: which of the variables in a cross-border order actually determine the outcome, and which are superstition. Practical detail welcome, however dull — the duller the better.
MikeKY_noInsulin said:The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines,…
Agreed, and hsCRP is worth reading alongside them. The inflammatory-marker fall is often the most striking change on a panel and it is consistent with the cardiovascular outcome data.
MikeKY_noInsulin said:The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines,…
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Import rules are jurisdiction-specific and this board keeps giving US-shaped answers to non-US questions. What is a personal-import allowance in one country is a controlled-import offence in another.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsAnswering the narrow version, because the broad one does not have a single answer. ApoB is the more informative number and it is cheap. LDL-C estimates cholesterol mass in atherogenic particles; ApoB counts the particles, and it is particle count that tracks risk — which is why the two can disagree and why the disagreement is the clinically interesting case. Triglycerides fall substantially with weight loss and improved insulin sensitivity, HDL moves modestly, and LDL-C often barely moves at all, which surprises people who expected everything to improve together.
Dr.BariatricHTX said:Agreed, and hsCRP is worth reading alongside them.
Mine went the same way, slower.